Searchable abstracts of presentations at key conferences in endocrinology

ea0026p30 | Adrenal cortex | ECE2011

Is plasma mitotane level >30 mg/l a serious adverse event in patients with adrenocortical carcinoma (ACC)?: a retrospective analysis of the French COMETE network

Mauclere-Denost S M D , Tabarin A T , Drui D D , Chaillous L C , Salenave S S , Leboulleux S L , Chabre O C , Do-Cao C D C , Dubourg H D , Cuvelier M L C , Young J Y , Baudin E B

Background: Mitotane antitumor efficacy is related to plasma levels. Objective responses have been associated with mitotane plasma levels >14 mg/l. However, high plasma levels >20 or >30 mg/l are at higher risk of toxicity, especially neurotoxicity. National-based survey is lacking to evaluate the frequency and severity of high mitotane plasma levels. Our aim was to retrospectively describe serious adverse events (SAE).Methods: Mitotane plasm...

ea0029oc7.1 | Adrenal Clinical | ICEECE2012

Progression-free survival without treatment of malignant pheochromocytoma and paraganglioma at one year

Hescot S. , Leboulleux S. , Amar L. , Borget I. , Vezzosi D. , Libe R. , Niccoli P. , Borson-Chazot F. , Do Cao C. , Tabarin A. , de la Fouchardiere C. , Raingeard I. , Chougnet C. , Gimenez-Roqueplo A. , Young J. , Bertherat J. , Wemeau J. , Bertagna X. , Schlumberger M. , Plouin P. , Baudin E.

Pheochromocytoma and paraganglioma are defined as malignant by the occurence of metastasis in extra paraganglionic sites. The natural evolution of these tumors remains unknown.The aim of our retrospective study was to define the progression-free survival (PFS) of untreated Malignant Pheochromocytoma and Paraganglioma (MPP) at 12 months (12 m-PFS) and to look for prognostic markers of 12 m-PFS. We analyzed clinical parameters of patients followed within 8...

ea0029oc9.1 | Endocrine Tumours & Translation | ICEECE2012

The Young Investigator Winner

Hadoux J. , Leboulleux S. , Al Ghuzlan A. , Borget I. , Caramella C. , Chougnet C. , Young J. , Dumont F. , Deschamps F. , Schlumberger M. , Baudin E.

Malignant pheochromocytoma and paraganglioma (PPGLs) are rare diseases with a heterogeneous behaviour. 131I-MIBG therapy and the cyclophosphamide-dacarbazine-vincristine chemotherapy regimen (CVD) constitute the most popular options in the metastatic setting. We have investigated the antitumor effect of temozolomide (TMZ), in patients with metastatic PPGLs. Efficacy was primary endpoint, safety and identification for prognosis factors of response were secondary endpoints.<...

ea0026p27 | Adrenal cortex | ECE2011

Do mitotane levels impact on the outcome of patients treated adjuvantly following radical resection of adrenocortical cancer (ACC)?

Ardito A , Al Ghuzian A , Fassnacht M , Daffara F , Leboulleux S , Wortmann S , Zaggia B , De Francia S , Volante Marco , Gonzaga Luigi , Berruti Alfredo , Allolio Bruno , Baudin Eric , Terzolo Massimo

We have demonstrated that adjuvant mitotane prolong recurrence free survival (RFS) in patients with radically resected ACC. Aim of the present study was to correlate mitotane levels with patient outcome in an adjuvant setting in 3 different referral centres in Europe. There were 120 patients (45 W, 75 M, median age 44 years, range 16–76) radically resected for ACC who were treated adjuvantly with mitotane from 1996 to 2010. ACC was stage I in 10 cases, II in 73, III in 31...

ea0026p72 | Endocrine tumours and neoplasia | ECE2011

Distribution of mitotane and its two metabolites in liproprotein fractions of patients with adrenocortical carcinoma

Cazaubon Y , Broutin S , Seck A , Remy H , Lemare F , Bidart J M , Chougnet C , Leboulleux S , Schlumberger M , Baudin E , Paci A

Introduction: Adrenocortical carcinoma (ACC) is a rare tumor of the adrenals with poor prognosis (survival rate for metastatic patients <15% at 5 years). Mitotane (o,p′-DDD) is the main therapeutic option with up to 66% objective response rates in patients with serum levels between 14 and 20 mg/l. Its two main metabolites are o,p′-DDA and o,p′-DDE which plasma levels are not correlated to therapeutic response. Mitotane is a lipophilic drug that accumulate...

ea0071013 | Bone impact of long-term replacement therapy with recombinant human parathyroid hormone (1-34) in adult patients with hypoparathyroidism evaluated by bone scintigraphy | BES2020

Bone impact of long-term replacement therapy with recombinant human parathyroid hormone (1–34) in adult patients with hypoparathyroidism evaluated by bone scintigraphy

R Fischler , AL Lecoq , F Besson , K Briot , S Salenave , C Goujart , S Leboulleux , E Carreira , L Bricaire , C Chabrolle , B Corvilain , C Philippe , A Linglart , G Grimon , P Kamenicky

Introduction: Recombinant human parathyroid hormone (rPTH) (1–34) is prescribed off-label in France for patients with hypoparathyroidism resistant to conventional therapy. However, the bone impact of this long-term replacement therapy is not well known.Objective: To determine the skeletal impact of chronic treatment with rPTH (1–34) in patients with hypoparathyroidism.Design: Single-center prospective study. Patients trea...

ea0029p1786 | Thyroid cancer | ICEECE2012

Is thyroid cancer recurrence risk increased after transplantation?

Tisset H. , Kamar N. , Faugeron I. , Pouteil-Noble C. , Klein M. , Frimat L. , Mourad G. , Drui D. , Do Cao C. , Vanthygem M. , Noel C. , Leenhardt L. , Rodien P. , Bonichon F. , Morelon E. , Leboulleux S. , Bournaud C. , Kelly A. , Niccoli P. , Schlumberger M. , Borson-Chazot F.

Context: An increased mortality by cancer is reported in grafted patients.Objective: This multicentric study aimed to investigate whether the prognosis of thyroid cancer was modified by transplantationResults: Sixty nine patients (35 M/34 F; median age 41 years) with a history of both thyroid cancer and transplantation were recruited via specialized networks (TUTHYREF and DIVAT). Evolution and outcome were retrospectively analyzed ...

ea0026p70 | Endocrine tumours and neoplasia | ECE2011

First prognostic analysis of stage III adrenocartical carcinoma patients after complete resection: a retrospective French Multicentric Study from the INCA-COMETE network

Do Cao C , Leboulleux S , Borget I , Bertherat J , De la Fouchardiere C , Hecart A C , Caron P , Tabarin A , Niccoli P , Rohmer V , Drui D , Schillo F , Raingeard I , Young J , Ghuzlan A , Borson-Chazot F , Bertagna X , Pattou F , Wemeau J L , Francis Z , Libe R , Aubert S , Baudin E

Objective: To assess outcome of stage III–ENSAT adrenocortical carcinoma (ACC) patients after complete macroscopic resection and prognostic factors for disease-free survival (DFS) and overall survival (OS).Methods: A retrospective review of 68 stage III ACC patients treated surgically between 1994 and 2009 in the French COMETE network was performed. Characteristics of patients were reviewed by a single investigator as well as the Weiss score by expe...